1. Home
  2. VGI vs GNLX Comparison

VGI vs GNLX Comparison

Compare VGI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VGI
  • GNLX
  • Stock Information
  • Founded
  • VGI 2012
  • GNLX 2001
  • Country
  • VGI United States
  • GNLX United States
  • Employees
  • VGI N/A
  • GNLX N/A
  • Industry
  • VGI Investment Managers
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VGI Finance
  • GNLX Health Care
  • Exchange
  • VGI Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • VGI 91.4M
  • GNLX 85.0M
  • IPO Year
  • VGI N/A
  • GNLX 2023
  • Fundamental
  • Price
  • VGI $7.91
  • GNLX $4.19
  • Analyst Decision
  • VGI
  • GNLX Strong Buy
  • Analyst Count
  • VGI 0
  • GNLX 4
  • Target Price
  • VGI N/A
  • GNLX $18.25
  • AVG Volume (30 Days)
  • VGI 46.0K
  • GNLX 293.9K
  • Earning Date
  • VGI 01-01-0001
  • GNLX 03-31-2025
  • Dividend Yield
  • VGI 12.66%
  • GNLX N/A
  • EPS Growth
  • VGI N/A
  • GNLX N/A
  • EPS
  • VGI N/A
  • GNLX N/A
  • Revenue
  • VGI N/A
  • GNLX $8,000.00
  • Revenue This Year
  • VGI N/A
  • GNLX N/A
  • Revenue Next Year
  • VGI N/A
  • GNLX N/A
  • P/E Ratio
  • VGI N/A
  • GNLX N/A
  • Revenue Growth
  • VGI N/A
  • GNLX N/A
  • 52 Week Low
  • VGI $6.68
  • GNLX $1.60
  • 52 Week High
  • VGI $7.99
  • GNLX $9.82
  • Technical
  • Relative Strength Index (RSI)
  • VGI 66.05
  • GNLX 70.02
  • Support Level
  • VGI $7.70
  • GNLX $3.20
  • Resistance Level
  • VGI $7.74
  • GNLX $4.23
  • Average True Range (ATR)
  • VGI 0.09
  • GNLX 0.53
  • MACD
  • VGI 0.03
  • GNLX 0.08
  • Stochastic Oscillator
  • VGI 90.91
  • GNLX 77.83

About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest

Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: